๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Treatment of neuroleptic malignant syndrome with levodopa

โœ Scribed by K. Otani; K. Mihara; T. Kondo; M. Okada; S. Kaneko; Y. Fukushima

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
400 KB
Volume
7
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

โœฆ Synopsis

Seven consecutive episodes of neuroleptic malignant syndrome in five cases were treated with 50-600 mg/day (mean 342 mg/day) of levodopa. In four episodes active pharmacological treatment was initiated with levodopa, while in the remaining three episodes it was introduced because of poor therapeutic response to dantrolene. Levodopa treatment brought complete recoveries in six out of the seven episodes. In the remaining episode, levodopa appeared to be at least partially effective, although it had to be discontinued prematurely because of vomiting. As complications of levodopa, psychotic symptoms developed in one case. The present report suggests that levodopa can be a first choice in the pharmacological treatment of neuroleptic malignant syndrome, although attention should be paid to the development of vomiting and psychotic symptoms as possible complications. It also supports the view that central hq podopaminergic states are the underlying pathophysiology in this syndrome.

KEY woRDs--Neuroleptic malignant syndrome, pharmacological treatment, levodopa.

๐Ÿ“œ SIMILAR VOLUMES

Neuroleptic malignant syndrome treated w
Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion
โœ M. E. Rodriguez; M. R. Luquin; G. Lera; G. Delgado; J. M. Salazar; Dr. Josรฉ A. O ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 262 KB

## Abstract A schizophrenic patient developed a characteristic clinical picture of neuroleptic malignant syndrome (NMS) while admitted to the hospital during an exacerbation of his psychiatric symptoms. Oral treatment of the NMS with bromocriptine (7.5 mg/day) or levodopa/carbidopa (125/12.5 mg) pr

Rhabdomyolysis without neuroleptic malig
Rhabdomyolysis without neuroleptic malignant syndrome induced by additional treatment of risperidone
โœ Norio Yasui; Tsuyoshi Kondo; Koichi Otani; Sunao Kaneko ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 65 KB

This is the ยฎrst case report of rhabdomyolysis without neuroleptic malignant syndrome induced by additional treatment of risperidone. The manifestations of this side eect were symptoms of myalgia, muscle weakness and redcoloured urine with ยฎndings of markedly elevated levels of creatine kinase and m

A case of tetrabenazine-induced neurolep
A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment
โœ Giselle M. Petzinger; Susan B. Bressman ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 404 KB

We report the case of a patient with tardive dystonia and a history of psychiatric illness who showed signs of neuroleptic malignant syndrome (NMS) after chronic treatment with tetrabenazine. The first symptom was a mental status change 'consisting of confusion, disorganized thinking, paranoid delus

Neuroleptic malignant syndrome with olan
Neuroleptic malignant syndrome with olanzapine associated with severe hypernatremia
โœ M. Samir Arnaout; Fouad P. Antun; Khalil Ashkar ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 39 KB

A 30-year-old white man with schizophrenia developed anorexia and nausea, and was admitted to hospital for confusion and delirium. He was on olanzapine, 10 days prior to admission. On admission, typical neuroleptic malignant syndrome (NMS) developed with elevated body temperature (39.7 degrees C), o